Skip to content

    Brain Cancer Health Center

    Font Size

    Neuroblastoma Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Recurrent Neuroblastoma


    Any child initially categorized as low risk who is older than 1 year at the time of metastatic recurrent or progressive disease and whose recurrence is not in the stage 4S pattern usually has a poor prognosis and should be considered for high-risk therapy.

    1. Treatment may consist of an aggressive regimen of combination chemotherapy.

    Recurrent Neuroblastoma in Patients Initially Classified as Intermediate Risk

    The treatment options for locoregional and metastatic recurrence in patients with intermediate-risk neuroblastoma are derived from the results of the COG-A3961 trial. Among 479 patients with intermediate-risk neuroblastoma treated on the COG-A3961 clinical trial, 42 patients developed disease progression. The rate was 10% of those with favorable biology and 17% of those with unfavorable biology. Thirty patients had locoregional recurrence, 11 had metastatic recurrence, and one had both types of recurrent disease. Six of the 42 patients died of disease, while 36 patients were salvaged. Thus, most patients with intermediate-risk neuroblastoma and disease progression may be salvaged.[8]

    Locoregional recurrence

    Treatment options for locoregional recurrent neuroblastoma initially classified as intermediate risk include the following:

    1. Surgery (complete resection).
    2. Surgery (incomplete resection) followed by chemotherapy.

    The current standard of care is based on the experience from the COG Intermediate-Risk treatment plan (COG-A3961). Locoregional recurrence of neuroblastoma with favorable biology that occurs more than 3 months after completion of chemotherapy may be treated surgically. If resection is less than near total, then additional chemotherapy may be given. Chemotherapy may consist of moderate doses of carboplatin, cyclophosphamide, doxorubicin, and etoposide. The cumulative dose of each agent is kept low to minimize permanent injury from the chemotherapy regimen, as used in a prior COG trial (COG-A3961).

    Metastatic recurrence

    Treatment options for metastatic recurrent neuroblastoma initially classified as intermediate risk include the following:

    1. High-risk therapy.

    Patients with metastatic recurrent neuroblastoma are treated like patients with newly diagnosed high-risk neuroblastoma. (Refer to the Treatment Options for High-Risk Neuroblastoma section of this summary for more information.)

    Recurrent Neuroblastoma in Patients Initially Classified as High Risk

    Any recurrence in patients initially classified as high risk signifies a very poor prognosis.[2] Clinical trials may be considered. Palliative care should be considered as part of the patient's treatment plan.

    1 | 2 | 3 | 4 | 5 | 6
    Next Article:

    Today on WebMD

    doctor and patient
    How to know when it’s time for home care
    doctory with x-ray
    Here are 10 to know.
    sauteed cherry tomatoes
    Fight cancer one plate at a time.
    Lung cancer xray
    See it in pictures, plus read the facts.
    Malignant Gliomas
    Pets Improve Your Health
    Headache Emergencies
    life after a brain tumor

    Would you consider trying alternative or complementary therapies?